NCT06816771 2025-02-10
Evaluation of the Efficacy and Safety of Pazopanib in Combination with TGI/CIV for Recurrent or Refractory Rhabdomyosarcoma in Children or Adolescents
Shandong Cancer Hospital and Institute
Phase 2 Recruiting
Clinical Trials
5 trialsNCT02203760 2024-11-15
PazoDoble
North Eastern German Society of Gynaecological Oncology
Phase 2 Active not recruiting
NCT01610206 2021-02-25
A Randomized Study of Safety and Efficacy of Pazopanib and Gemcitabine in Persistent or Relapsed Ovarian Cancer
University of Virginia
Phase 2 Completed
NCT01713296 2015-10-08
Pazopanib in Relapsed and Refractory Small Cell Lung Cancer
Hellenic Oncology Research Group
Phase 2 Completed
NCT00430781 2015-05-08
Pazopanib Plus Lapatinib Compared to Lapatinib Alone and Pazopanib Alone In Subjects With Metastatic Cervical Cancer
GlaxoSmithKline
Phase 2 Completed